Clinical trial
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for…
NCT04047628 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Recruiting
Key facts
| NCT number | NCT04047628 |
|---|---|
| Title | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) |
| Official title | A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) |
| Acronym | BEAT-MS |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) Blood and Marrow Transplant Clinical Trials Network PPD Development, LP Industry Rho Federal Systems Division, Inc. |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis |
| Intervention type | Biological, Procedure |
| Interventions | Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) |
| Enrollment | 156 |
| Start date | Dec 19, 2019 |
| Primary completion | Oct 1, 2026 |
| Completion | Oct 1, 2029 |
| First posted | Aug 7, 2019 |
| Last update posted | Jan 6, 2026 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: